



Funxional Therapeutics successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action

Cambridge (UK). 8th July 2009. Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

“We are extremely pleased with the outcome of this initial clinical study with FX125L” said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. “The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L”.

About Funxional Therapeutics Ltd

Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) that focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge.

For more information about FXT, please visit our web site (www.funxionaltherapeutics.com) or contact us by e-mail (info@funxionaltherapeutics.com).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases.

BSCIs are one of the three proprietary technology platforms in FXT’s portfolio all of which originated in the University of Cambridge. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.

For enquiries regarding this press release, please contact Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics, at +44 1223 451095.